12 Dec 2024 Dose Escalation and Recommended Dose for Expansion (RDE) Arms of the AVA6000 Phase 1a Trial complete and Phase 1b Disease Specific Expansion Cohorts Open for Enrolment Investors | Therapeutics
27 Nov 2024 Peel Hunt Healthcare & Life Sciences Podcast with Christina Coughlin Investors | Podcasts and Videos | Therapeutics
08 Nov 2024 Video presentations from R&D Spotlight: ‘Next Generation of pre|CISION® Medicines’ Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics
24 Oct 2024 Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona Investors | Therapeutics
21 Oct 2024 Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology Investors | Therapeutics
17 Oct 2024 Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION® Platform Investors | Therapeutics
15 Oct 2024 Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific Officer Investors | Therapeutics
10 Oct 2024 Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium Investors | Therapeutics
24 Sep 2024 ESMO poster data video presentation by Christina Coughlin Investors | Podcasts and Videos | Therapeutics